For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Humana Inc. (HUM) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Low · Gem Score -38 (−100…+100 Quality+Value blend) · Quality 1 · Value -69 · Sentiment -24 (timing only, not weighted) · Composite fair value $306.27 vs $384.31 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Humana Inc.
HUM NYSEHumana Inc. is a U.S.-based health insurance and healthcare services company headquartered in Louisville, Kentucky. The company focuses on providing medical and specialty insurance products, with a particular emphasis on Medicare-related offerings for seniors, including individual and group Medicare Advantage plans, stand-alone prescription drug plans, Medicare supplement policies, and ancillary coverage such as dental, vision, life, and disability insurance. Humana also administers healthcare services for military members, retirees, and their families through administrative service contracts. Through its CenterWell segment, Humana operates senior-focused primary care centers, home health services, and pharmacy and hospice solutions, integrating clinical care with insurance to support coordinated, value-based care. By combining insurance products with direct healthcare delivery capabilities, Humana plays a significant role in the managed healthcare sector, serving individuals, employers, and government-sponsored programs across the United States.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 9.84
Total Equity: $17.74B
Shares: 120,826,000
Total Debt: $12.37B
Cash: $4.20B
EBITDA: $3.40B
Total Debt: $12.37B
Cash: $4.20B
Revenue: $129.66B
Revenue: $129.66B
Revenue: $129.66B
Total Equity: $17.74B
Tax Rate: 17.4%
Equity: $17.74B
Total Debt: $12.37B
Cash: $4.20B
Current Liabilities: $16.35B
Long-Term Debt: $12.37B
Total Debt: $12.37B
Total Equity: $17.74B
Shares: 120,826,000
Shares: 120,826,000
CapEx: -$546.00M
Shares: 120,826,000
Stock Price: $384.31
Net Income: $1.19B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 18, 2026 12:36am (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $83.1B | $92.9B | $106.4B | $117.8B | $129.7B |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | $10.1B | $12.7B | $13.2B | $13.7B | $15.5B |
| Operating Income | $3.1B | $3.8B | $4.0B | $2.6B | $2.7B |
| Net Income | $2.9B | $2.8B | $2.5B | $1.2B | $1.2B |
| EBITDA | $3.7B | $4.5B | $4.8B | $3.4B | $3.4B |
| EPS | $22.79 | $22.20 | $20.09 | $10.01 | $9.87 |
| EPS (Diluted) | $22.67 | $22.08 | $20.00 | $9.98 | $9.84 |
Balance Sheet (Annual)
Last updated: Aug 18, 2026 12:21am (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $3.4B | $5.1B | $4.7B | $2.2B | $4.2B |
| Total Current Assets | $24.9B | $26.2B | $30.0B | $29.8B | $32.7B |
| Total Assets | $44.4B | $43.1B | $47.1B | $46.5B | $48.9B |
| Current Liabilities | $15.3B | $17.2B | $18.9B | $16.9B | $16.3B |
| Long-Term Debt | $10.5B | $9.0B | $10.2B | $11.1B | $12.4B |
| Total Liabilities | $28.3B | $27.7B | $30.7B | $30.0B | $31.2B |
| Total Equity | $16.1B | $15.4B | $16.3B | $16.4B | $17.7B |
| Retained Earnings | $23.1B | $25.5B | $27.5B | $28.3B | $29.1B |
Cash Flow (Annual)
Last updated: Aug 18, 2026 12:36am (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $2.3B | $4.6B | $4.0B | $3.0B | $921.0M |
| Capital Expenditure | -$1.3B | -$1.1B | -$1.0B | -$575.0M | -$546.0M |
| Free Cash Flow | $946.0M | $3.5B | $3.0B | $2.4B | $375.0M |
| Acquisitions (net) | -$4.2B | -$337.0M | -$233.0M | -$89.0M | -$81.0M |
| Net Debt Issued / (Repaid) | $3.0B | $2.0B | $2.5B | $2.2B | $1.5B |
| Dividends Paid | -$354.0M | -$392.0M | -$431.0M | -$431.0M | -$430.0M |
| Stock Buybacks | -$79.0M | -$2.1B | -$1.6B | -$817.0M | -$151.0M |
| Net Change in Cash | -$1.3B | $1.7B | -$367.0M | -$2.5B | $2.0B |
Growth Trends (YoY %)
Last updated: Aug 18, 2026 12:36am (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +11.8% | +14.5% | +10.7% | +10.1% |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | +20.7% | +5.6% | -36.2% | +5.5% |
| Net Income Growth | -4.3% | -11.3% | -51.5% | -1.6% |
| EBITDA Growth | +20.4% | +6.3% | -29.0% | +0.0% |
Dividend History (Last 20)
Last updated: Aug 12, 2026 10:19am (11d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-06-26 | $0.89 | — | — | — |
| 2026-03-27 | $0.89 | — | — | — |
| 2025-12-26 | $0.89 | — | — | — |
| 2025-09-26 | $0.89 | — | — | — |
| 2025-06-27 | $0.89 | — | — | — |
| 2025-03-28 | $0.89 | — | — | — |
| 2024-12-31 | $0.89 | — | — | — |
| 2024-09-30 | $0.89 | — | — | — |
| 2024-06-28 | $0.89 | — | — | — |
| 2024-03-27 | $0.89 | — | — | — |
| 2023-12-28 | $0.89 | — | — | — |
| 2023-09-28 | $0.89 | — | — | — |
| 2023-06-29 | $0.89 | — | — | — |
| 2023-03-30 | $0.89 | — | — | — |
| 2022-12-29 | $0.79 | — | — | — |
| 2022-09-29 | $0.79 | — | — | — |
| 2022-06-29 | $0.79 | — | — | — |
| 2022-03-30 | $0.79 | — | — | — |
| 2021-12-30 | $0.70 | — | — | — |
| 2021-09-29 | $0.70 | — | — | — |
Deep Analysis
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-19 08:59Recovery pays +447%; another quarter like the worst recent one costs 79%. Ratio 5.6:1.
| Case | Growth | Margin | Fair value | vs price ($384.31) |
|---|---|---|---|---|
| Bull — recovery | +22% | 9.2% | $2,102.49 | +447% |
| Base — stabilizes | +15% | 8.0% | $1,457.54 | +279% |
| Bear — keeps slipping | +7% | 6.8% | $977.71 | +154% |
| Stress — last quarter repeats | +11% | 0.4% | $79.40 | -79% |
Narrative Economics
market-narrative step).
AI Lens 4th lens · how AI reaches this business · 5-yr
2026-08-18Under capitated Medicare Advantage economics Humana keeps whatever care it avoids: AI-driven risk stratification, documentation automation in CenterWell primary care and home health, and pharmacy/claims automation convert directly into medical and admin cost that never gets incurred.
MA is a bid-based market — administrative savings tend to be recycled into richer benefits to win members rather than retained as margin, while providers deploy their own AI to maximize documented acuity and appeal denials, pushing the medical loss ratio the other way.
Whether AI-enabled savings show up as SG&A ratio decline AND stable-to-better benefit-adjusted MLR, versus being spent back in bids. Watch admin expense ratio, MA margin per member, and CenterWell patient-per-clinician panel size across bid cycles.
CMS contracts and star ratings, state licenses and statutory capital, decades of senior-cohort claims and risk-adjustment data, and the owned CenterWell/home-health/pharmacy delivery footprint — none of which cheap software reproduces.
AI Lens thesis
Humana's job — bear medical risk for seniors and manage their care — is untouched by cheaper intelligence; what changes is the cost of doing it. Roughly an eighth of revenue is administration (service centers, utilization review, coding, appeals, enrollment), a highly automatable information-processing stack, and Humana now owns delivery assets where AI raises clinician throughput under capitation rather than merely billing more visits. Against that: the monetized unit is a CMS-set PMPM bid, so competitive dynamics push savings into benefits; provider-side AI escalates the coding and denial-appeal arms race; RADV audit exposure means AI-assisted risk-adjustment coding cuts both ways; and Humana's use of predictive algorithms in post-acute coverage decisions is already a litigation and regulatory target. AI-native insurers face licensing, capital, network, and star-rating barriers that code does not solve, so entrant compression is limited. Net: modest structural improvement to a thin-margin, regulation-priced business — not a re-rating mechanism.
What the market may be underestimating
Upside Capitated senior primary care is the rare setting where AI productivity gains accrue to the risk-bearer: raising CenterWell panel sizes without new physicians compounds into both provider margin and lower plan-level utilization simultaneously.
Downside Asymmetric AI adoption by hospitals and post-acute providers — automated documentation, acuity upcoding, and mass denial appeals — can raise Humana's medical and appeals cost faster than its own automation lowers admin cost.
Outcome range spread 41
Growth Outlook
Analyzed 2026-08-18 00:45The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
The raw numbers tell a story the models are partially missing. Revenue growth is genuine and accelerating: Q1 2026 at $39.65B vs Q1 2025 at $32.11B is 23.5% YoY, well above the 10% trailing CAGR — that's not a company in "existential crisis" on the top line. But margins are the tell: Q1 2026 net margin of 3.0% is actually the best print in the last eight quarters, yet still worse than the 3.5% average of 2021-2023. Operating income collapsed from $4.01B in 2023 to $2.70B in 2025 while revenue grew 22% — the medical loss ratio problem is real and has cost roughly $1.3B of annualized operating earnings. FCF of $375M against a $46B market cap is a 0.8% FCF yield, which is genuinely alarming for a "mature earner." The 39x P/E is not on normalized earnings — it's on trough earnings, which is the more charitable framing.
I largely agree with the synthesis verdict of overvalued but I think Market Forces overshoots into melodrama. "Existential crisis" and "avoid or short" doesn't square with $129.7B in revenue growing 10%+ and a Q1 2026 that showed sequential margin recovery ($1.19B NI on $39.65B, best quarter since Q1 2025). This is a cyclical margin trough in a regulated oligopoly with demographic tailwinds, not a Blockbuster moment. The Narrative Economics layer is closer to right: this is a turnaround bet trading at a ~49% premium to a DCF that assumes normalized MA margins. The disagreement between "avoid/short" and a $258 DCF fair value (still only 33% downside) is itself a contradiction the reader should notice — one of these models is calibrated wrong, and I think it's Market Forces.
The contrarian case worth taking seriously: if 2025 truly was the peak MLR year — CMS 2026 rate notice was more favorable than feared, and Star ratings litigation is trending Humana's way — then normalized EPS could rebuild toward the 2022-2023 range of ~$22-25/share, putting the stock at 15-17x normalized earnings, which is reasonable for a defensive healthcare name. The Q1 2026 print of $1.19B NI annualized ($4.76B) would already imply ~$40 EPS if sustained, though Q1 is seasonally strongest for MA insurers so that's misleading. The bigger contrarian flag: CenterWell has never been separately valued for readers, and if you assign it even 2x revenue on ~$5B of care-delivery revenue, that's $10B of the market cap — meaning the insurance core is trading at ~$36B or roughly 0.28x sales, which is cheap versus UNH/ELV. The models don't disaggregate this.
Where the data is thin: I have zero meaningful insider signal (two 544-share awards is noise), no gross margin line, and no segment breakout between insurance and CenterWell — all of which are essential to properly value this. The balance sheet is fine but not fortress: $12.4B debt vs $4.2B cash and only $921M operating CF means debt paydown flexibility is limited if MLR pressures persist another year. ROE of 6.7% and ROIC of 8.6% are below Humana's cost of capital, which supports the overvalued read regardless of narrative. I dissent partially from the synthesis — I think fair value is closer to $300-320 than $258 because the Q1 2026 margin inflection is real and the DCF likely under-weights the CenterWell option value — but I agree the current $384 price is not defensible on either trailing or forward normalized earnings without heroic MLR recovery assumptions. Wait for Q2 to confirm the margin trajectory; a re-rating to $340 on a soft print would be the entry.
GPT Reading
Humana’s numbers read like a business whose top line is still healthy but whose economics have badly degraded, and the stock still assumes that degradation is temporary. Revenue went from $83.1B in 2021 to $129.7B in 2025, a strong 12%-plus annualized climb, and the latest quarter was again solid on sales at $39.65B, up 23% from $32.11B a year earlier. But nearly every profitability line says the growth is low quality. Annual operating income was $4.01B in 2023 and then fell to $2.56B in 2024 and only $2.70B in 2025 despite another $11.9B of revenue added in 2025. Net income has effectively been cut in half from $2.49B in 2023 to $1.19B in 2025, and operating margin is now just 2.1% with net margin 0.9% on a $130B revenue base. That is a razor-thin outcome for a company trading at 39x earnings.
The quarterly pattern is even more revealing. Humana is not showing a clean margin rebound; it is showing repeated seasonality plus structurally weaker profitability. In 2024 and 2025, the fourth quarter was loss-making both years, at -$693M and -$796M respectively. The “good” quarters are not that good either: Q2 and Q3 of 2025 produced just $545M and $195M of net income on more than $32B of revenue each, or margins of 1.7% and 0.6%. Even the latest Q1 2026, which looks decent at $1.19B of earnings, is basically flat versus Q1 2025’s $1.24B despite revenue being up by $7.5B year over year. In other words, Humana needed 23% more revenue to deliver slightly less profit. That is not the signature of a franchise about to snap back; it is the signature of reimbursement/cost pressure overwhelming scale.
Cash flow reinforces the concern. On $1.19B of annual net income in 2025, operating cash flow was only $921M and free cash flow just $375M after $546M of capex. Against a $46.2B market cap, that is an FCF yield under 1%. Even if one argues 2025 was abnormally depressed, the current valuation leaves almost no room for that argument to be only partly right. Balance sheet risk is not acute — $12.37B of debt against $17.74B of equity and a 2.0x current ratio is manageable — but it does not compensate for weak earnings power. At 2.6x book, 16x EV/EBITDA, and 39x earnings, investors are not paying for a troubled insurer; they are paying for a recovery in returns that the reported data has not yet delivered. For a payer with ROE of 6.7% and ROA of 2.4%, that is too rich.
The best case against my view is straightforward: Humana is a Medicare Advantage-heavy company, and these businesses can look optically broken at the trough of a cost cycle and then recover quickly when pricing catches up. Revenue growth remains strong, Q1 2026 margin did improve sequentially back to 3.0%, and annual net income in 2025 at $1.19B was at least slightly stable versus $1.21B in 2024 rather than collapsing further. A bull would also point out that low P/S of 0.36x and EV/revenue of 0.42x are typical signals that managed care names are being valued on normalized margins, not current margins, because the balance sheet carries float-like liabilities and the income statement is unusually cyclical to medical cost trends. If margins merely recover to something closer to 2023, the current multiple on depressed earnings could unwind into a much lower forward P/E very quickly.
I weigh that differently because the burden of proof is on the recovery thesis, and the current data does not show operating leverage in the right direction. Since 2023, Humana has added over $23B of annual revenue and lost roughly $1.3B of net income. That is not a one-quarter wobble. For me to change my mind, I would need to see at least two things together: first, quarterly earnings converting incremental revenue into materially better margins, meaning multiple quarters above 2.5%-3.0% net margin rather than one strong Q1 offset by weak Q2-Q4; second, cash flow normalization, with annual operating cash flow comfortably back above $2.5B and free cash flow over $1.5B. If Humana can show that 2025 was the trough and 2026-2027 earnings power is really back toward the 2023 level or better, the stock can be defended. Without that evidence, $384 looks like paying a turnaround multiple for a company still reporting deterioration.
Grok Reading
The numbers describe a mature Medicare Advantage carrier whose top line is still compounding at roughly 10 percent while profitability has been cut in half. Revenue climbed from $83 billion in 2021 to $130 billion in 2025, yet net income fell from $2.93 billion to $1.19 billion and operating income collapsed from a $4.0 billion peak in 2023 to $2.7 billion. Trailing net margin sits at 0.9 percent, ROE at 6.7 percent, and free cash flow at just $375 million—less than 0.3 percent of sales—after only $921 million of operating cash flow. The quarterly pattern is equally stark: three of the last eight quarters produced losses or sub-1 percent margins, bookended by a seasonally strong $1.24 billion print in early 2025 and a $1.19 billion rebound in the March 2026 quarter on $39.7 billion of revenue. That latest quarter is real improvement, but it does not erase an earnings CAGR of minus 31 percent or an FCF CAGR of minus 65 percent. At $384 the stock trades at 39 times those depressed earnings, 2.6 times book, and 16 times EBITDA—multiples that embed a full recovery in medical cost ratios and a durable payoff from the CenterWell vertical stack that the cash-flow statement has not yet validated.
The valuation synthesis’s $258–$306 fair-value range is directionally correct; the roughly $126 premium to the lower DCF anchor is almost pure narrative. Revenue quality is high and the balance sheet is serviceable—$4.2 billion cash, 0.70 debt-to-equity, current ratio above 2—but none of that justifies paying growth-insurer multiples for mid-single-digit returns on capital in a business whose core MA franchise is under regulatory and actuarial pressure. The market is pricing the turnaround as largely complete; the income statement says it is only beginning, if it arrives at all.
The strongest contrary case rests on the March 2026 quarter and the structural demography. A 3 percent net margin on nearly $40 billion of quarterly revenue, if sustained, annualizes to something closer to $4–5 billion of net income and would make the 39 times multiple look less absurd on forward earnings. Aging enrollment, still-underpenetrated MA, and any CMS rate relief could expand the top line another 8–10 percent while CenterWell’s owned primary-care and home-health assets gradually pull medical loss ratios lower—exactly the bull story the narrative layer describes. Competitors without the same care-delivery footprint may not match those unit economics, and a re-rating toward 15–18 times normalized earnings would support prices near or above the current quote. I weigh this less heavily because one strong quarter follows a $796 million loss, cumulative FCF remains anemic, and Star-rating and coding headwinds have already proven they can overwhelm integration gains for multi-year stretches.
I would reverse to neutral or constructive only if the next two reported quarters sustain net margins above 2.5 percent with sequential MLR improvement, full-year 2026 free cash flow exceeds $1.5 billion, and management guides 2027 operating margin back toward the 3.5–4 percent zone last seen in 2022–23 without relying on one-time reserve releases.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Humana is a mature managed-care franchise with $19.9B in liquid cash, net cash of $7.5B, an Altman Z of 4.96, and OCF/NI of 1.45x - the survival math is not in question and earnings-quality mechanicals are clean (accruals -1.8% of assets). Capital discipline is a genuine plus: diluted shares fell from 129.4M to 120.8M (a -1.7% CAGR) with buybacks running 462.8% of SBC and SBC only 0.2% of revenue. That is unusually shareholder-friendly for a healthcare insurer. The concern is operational trajectory. Revenue grew from $83.1B to $129.7B (2021 to 2025), but operating margin compressed from 3.8% to 2.1%, net income halved from $2.93B to $1.19B, and FCF collapsed from $3.47B in 2022 to just $375M in 2025 - an 84% drop in the most recent year. That pattern is consistent with the well-known Medicare Advantage medical-cost / STAR ratings pressure the industry has faced, and it means the 'self-funding' label is currently thin: $375M of FCF against a business that historically threw off $2-3B+. Insider tape shows no open-market P or S prints - just small routine awards - so no directional signal. Overall this is a durable, well-capitalized business going through a real earnings drawdown, not a broken one.
Verify before trusting this (5)
- Medicare Advantage medical-loss ratio trend and 2026 STAR ratings outcome
- Working capital / medical claims payable swings driving the 2025 FCF drop - is it timing or structural?
- Segment mix: Insurance vs CenterWell contribution to the operating margin compression
- Any pending divestitures or restructuring charges embedded in 2024-2025 operating income
- Regulatory / DOJ risk-adjustment audit exposure disclosed in the 10-K
Price is $384.31 vs a composite fair value of $306 and a signal-adjusted FV of $258 - roughly 20-33% above deserved. The three methods triangulate a wide band: DCF at $394 (essentially at spot, but this method extrapolates a recovery), EPV floor at $267 (what today's depressed earnings power actually supports), and anchored P/E at just $170 (reflecting the collapsed EPS base). The honest read is that only the DCF - the most assumption-heavy method - justifies the tape; the two backward-looking anchors say the stock is meaningfully rich. With operating margin halved and FCF down 84% YoY, the EPV of $267 is the more defensible near-term anchor, and price sits ~44% above it. Quality is Solid (fortress balance sheet, clean cash conversion, high earnings quality) which lifts deserved value toward the DCF end of the range - but a Solid business in an earnings squeeze does not deserve a premium to its own composite FV. What's priced in: MA margin normalization, successful CenterWell monetization, and no further MLR deterioration. That is the bull case as the base case. If MLR keeps drifting or MA rate notices disappoint, the anchored-PE regime ($170s) becomes the gravitational center, not the DCF.
Verify before trusting this (5)
- Next MA bid cycle and CMS rate notice - directly resets deserved value
- MLR trajectory over next 2 quarters - is the sicker-cohort issue transitory or structural
- CenterWell segment margin disclosure and clinic-level unit economics
- FCF recovery pace vs the 84% YoY collapse - one-time or new baseline
- Any buyback pause or dividend signal that would flag internal caution
The macro tape is mildly risk-on with a calm VIX, which normally helps cyclicals more than a low-beta (0.74) managed-care name like HUM — so the market regime is a soft, non-decisive tailwind here. Stock-specific news flow is genuinely mixed: a clean earnings beat and quality-of-earnings improvements on 8/15 support the bull turnaround story, but the same 72-hour window carries a very damaging sector headline ('Medicare Advantage providers are cutting plans') that directly attacks the MA-penetration thesis powering HUM's narrative premium. The turnaround-bet archetype has strong intensity but only moderate durability and low cult coefficient, meaning the story has no fanbase to defend it when MLR or MA-pricing headlines hit. The July 29 tape reaction — beating revenue and EPS yet dropping ~6% on a raised medical cost ratio — is the tell: analyst tone is skeptical, and the market is punishing any crack in the margin story regardless of the headline print. Momentum is modestly positive and volatility is low, so there is no runaway sentiment either way. Net: the risk-on tape and beat-driven relief roughly offset the MA-cut narrative and MLR skepticism, leaving pressure balanced with a slight negative tilt on narrative durability.
Verify before trusting this (4)
- Whether the MA-plan-cuts story broadens into a sector de-rating or fades in a week
- Next MLR / medical cost ratio commentary from HUM or peers (UNH, ELV, CVS) — the true sentiment fulcrum
- CMS / regulatory headlines on 2027 MA rate notice or benchmark pressure
- Analyst target revisions post the 8/15 beat — upgrades would validate the turnaround narrative
Humana's job — bear medical risk for seniors and manage their care — is untouched by cheaper intelligence; what changes is the cost of doing it. Roughly an eighth of revenue is administration (service centers, utilization review, coding, appeals, enrollment), a highly automatable information-processing stack, and Humana now owns delivery assets where AI raises clinician throughput under capitation rather than merely billing more visits. Against that: the monetized unit is a CMS-set PMPM bid, so competitive dynamics push savings into benefits; provider-side AI escalates the coding and denial-appeal arms race; RADV audit exposure means AI-assisted risk-adjustment coding cuts both ways; and Humana's use of predictive algorithms in post-acute coverage decisions is already a litigation and regulatory target. AI-native insurers face licensing, capital, network, and star-rating barriers that code does not solve, so entrant compression is limited. Net: modest structural improvement to a thin-margin, regulation-priced business — not a re-rating mechanism.
None surfaced.
Verify before trusting this (8)
- SG&A ratio vs benefit richness
- MA margin per member per month
- Bid strategy commentary
- MA enrollment penetration trend
- CMS benchmark growth rates
- Age-in cohort volumes
- Statutory capital adequacy
- Litigation over algorithmic denials
The demand substrate is demographic and non-discretionary: seniors aging into Medicare with a majority now choosing Advantage. What broke 2023-2025 was not demand but price-cost timing — post-pandemic utilization normalization plus coding and rate changes arriving faster than bids could adjust. That is a lagging, self-correcting mechanism, and the industry is two bid cycles into correcting it. The durable structural questions are different: a single government counterparty holds pricing and audit discretion, and entitlement fiscal pressure gives it motive to use it. Higher rates modestly help investment income on float. Nothing in the current macro (neutral, 10y ~4.7%, positive curve) materially changes senior insurance volumes.
When we made this prediction on Aug 18, 2026, HUM was $384.31. We expect it to be $332.00 by Feb 2027, and we consider it great value under $270.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 18, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.